Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22074428 | 0.92 | S1PR1 (0.52) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22077167 | 0.87 | S1PR1 (0.60) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22074559 | 0.86 | S1PR1 (0.61) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22074554 | 0.85 | S1PR1 (0.60) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22074494 | 0.85 | S1PR1 (0.58) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22074425 | 0.85 | S1PR1 (0.51) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22074557 | 0.83 | S1PR1 (0.58) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL24201480 | 0.81 | S1PR1 (0.48) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22077202 | 0.81 | S1PR1 (0.61) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL22077160 | 0.80 | S1PR1 (0.49) | S1PR1S1PR4S1PR5ADORA3S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017513-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3892616-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020114475-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | 上海济煜医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017513-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR4 4/4885S1PR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.